These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 29666300)

  • 1. A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations.
    Tamborero D; Rubio-Perez C; Muiños F; Sabarinathan R; Piulats JM; Muntasell A; Dienstmann R; Lopez-Bigas N; Gonzalez-Perez A
    Clin Cancer Res; 2018 Aug; 24(15):3717-3728. PubMed ID: 29666300
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
    Giraldo NA; Becht E; Vano Y; Petitprez F; Lacroix L; Validire P; Sanchez-Salas R; Ingels A; Oudard S; Moatti A; Buttard B; Bourass S; Germain C; Cathelineau X; Fridman WH; Sautès-Fridman C
    Clin Cancer Res; 2017 Aug; 23(15):4416-4428. PubMed ID: 28213366
    [No Abstract]   [Full Text] [Related]  

  • 3. Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs.
    Varn FS; Schaafsma E; Wang Y; Cheng C
    Cancer Res; 2018 Nov; 78(22):6413-6423. PubMed ID: 30254145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathways- and epigenetic-based assessment of relative immune infiltration in various types of solid tumors.
    Bacolod MD; Barany F; Pilones K; Fisher PB; de Castro RJ
    Adv Cancer Res; 2019; 142():107-143. PubMed ID: 30885360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials.
    Roller A; Davydov II; Schwalie PC; Serrano-Serrano ML; Heller A; Staedler N; Ferreira CS; Dietmann G; Klaman I; Valdeolivas A; Korski K; Cannarile MA
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38649280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptomic Features of T Cell-Barren Tumors Are Conserved Across Diverse Tumor Types.
    Routh ED; Pullikuth AK; Jin G; Chifman J; Chou JW; D'Agostino RB; Seino KI; Wada H; Print CG; Zhang W; Lu Y; Miller LD
    Front Immunol; 2020; 11():57. PubMed ID: 32117236
    [No Abstract]   [Full Text] [Related]  

  • 7. Classifying Cancers Based on T-cell Infiltration and PD-L1.
    Teng MW; Ngiow SF; Ribas A; Smyth MJ
    Cancer Res; 2015 Jun; 75(11):2139-45. PubMed ID: 25977340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.
    Charoentong P; Finotello F; Angelova M; Mayer C; Efremova M; Rieder D; Hackl H; Trajanoski Z
    Cell Rep; 2017 Jan; 18(1):248-262. PubMed ID: 28052254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy.
    Davoli T; Uno H; Wooten EC; Elledge SJ
    Science; 2017 Jan; 355(6322):. PubMed ID: 28104840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.
    Li B; Severson E; Pignon JC; Zhao H; Li T; Novak J; Jiang P; Shen H; Aster JC; Rodig S; Signoretti S; Liu JS; Liu XS
    Genome Biol; 2016 Aug; 17(1):174. PubMed ID: 27549193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist.
    Fend L; Gatard-Scheikl T; Kintz J; Gantzer M; Schaedler E; Rittner K; Cochin S; Fournel S; Préville X
    Cancer Immunol Res; 2014 Dec; 2(12):1163-74. PubMed ID: 25168392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments.
    Yu JW; Bhattacharya S; Yanamandra N; Kilian D; Shi H; Yadavilli S; Katlinskaya Y; Kaczynski H; Conner M; Benson W; Hahn A; Seestaller-Wehr L; Bi M; Vitali NJ; Tsvetkov L; Halsey W; Hughes A; Traini C; Zhou H; Jing J; Lee T; Figueroa DJ; Brett S; Hopson CB; Smothers JF; Hoos A; Srinivasan R
    PLoS One; 2018; 13(11):e0206223. PubMed ID: 30388137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
    Ahern E; Harjunpää H; Barkauskas D; Allen S; Takeda K; Yagita H; Wyld D; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2017 Oct; 23(19):5789-5801. PubMed ID: 28634284
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies.
    Kosoff D; Krueger T; Lang JM
    Immunotherapy; 2013 Nov; 5(11):1243-54. PubMed ID: 24188678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure.
    Lin Z; Huang L; Li S; Gu J; Cui X; Zhou Y
    Sci Rep; 2020 Dec; 10(1):21530. PubMed ID: 33299035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating RNA expression and visual features for immune infiltrate prediction.
    Reiman D; Sha L; Ho I; Tan T; Lau D; Khan AA
    Pac Symp Biocomput; 2019; 24():284-295. PubMed ID: 30864330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 19. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.
    Duhen T; Duhen R; Montler R; Moses J; Moudgil T; de Miranda NF; Goodall CP; Blair TC; Fox BA; McDermott JE; Chang SC; Grunkemeier G; Leidner R; Bell RB; Weinberg AD
    Nat Commun; 2018 Jul; 9(1):2724. PubMed ID: 30006565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer.
    Balli D; Rech AJ; Stanger BZ; Vonderheide RH
    Clin Cancer Res; 2017 Jun; 23(12):3129-3138. PubMed ID: 28007776
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.